List view / Grid view
How will a new regulatory landscape impact the EU and UK pharma industries? Early 2022 will see major new clinical trial legislation come into effect, with proposals for an entirely new regulatory regime promised by the end of the year. Paul Ranson, Consultant at Morgan Lewis, reflects on this and…
Following his first full year as Managing Director UK, Ireland & Nordics for Novartis Pharmaceuticals, healthcare leader Chinmay Bhatt shares his learnings from the pandemic and reflects on what’s next.
Making the decision on which type of pure water you need for your application can be difficult. This blog provides a quick guide to pure water types.
The brain is protected by the blood-brain barrier, a multi-layered structure which helps to protect it from the invasion of pathogens or unwanted substances and limits drug transport into the brain via the bloodstream. Here, Dr Oliver Ernst and Dr Heiko Manninga from German biotech company NEUWAY Pharma share details of…
Is the future of cell and gene therapy autologous or allogeneic? Which solid tumour may receive the first cell therapy treatment? How will the use of ATMPs in cancer care change our healthcare structures in years to come? Discover all this and more in this podcast with bioMérieux.
Articles featured in this in-depth focus discuss a technology enabling drugs to be delivered across the blood-brain barrier, the potential of targeted radionuclide therapy as a precision oncology treatment and novel bioconjugation methods to improve biologics drug delivery.
Articles in this in-depth focus explore the applications of portable spectrometers and review their critical features, as well as comparing the results of standard and miniaturised NIR spectroscopy sensors in medicinal plant QC.
At ELGA we are dedicated to providing water system solutions that empower scientists and researchers worldwide to do what they do best, uninterrupted.
In our latest journal, discover the innovations enabling drugs to be delivered across the blood-brain barrier, the challenges associated with downstream purification of cell and gene therapies, as well as applications of NIR spectroscopy in ingredient analysis. Also featured in this issue, explore the development and future potential of radiomolecular…
The U.S. Food and Drug Administration (FDA) has taken new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction.
Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility.
EMA will establish the DARWIN EU® Coordination Centre to develop and manage a network of real-world healthcare data sources across the EU.
Download this whitepaper to find out how the purity of bottled water compares to the purity of water produced by an ELGA water purification system.
In this article, Karen Ooms, Head of Statistics at Quanticate, compares the rule- and model-based approaches to Phase I trial design, exploring their benefits and weaknesses in defining maximum tolerated dose for oncology products.
The impending ‘Bio Revolution’, with the microbiome at its foundation, offers ground-breaking solutions and a wealth of opportunity in data science and bioinformatics, explains Anthony Finbow of Eagle Genomics.
